CONNECTGENE
Genomics Oncology

Unlock the Power of Genomics

ONCOMINE™ FOCUS TUMOUR ANALYSIS

The Oncomine™ Focus Tumour Analysis is a targeted, next-generation sequencing assay that allows for the detection of hundreds of mutations across 52 genes commonly implicated in a range of cancer types.

By sequencing using the Oncomine™ Focus Assay, we can establish the molecular profile of your tumour. We can then use this information to build your personalised report and provide you with potential targeted therapies and clinical trials that you may be able to access based on the unique genetic makeup of your tumour.

This can aid you and your health care professional in developing the best and most effective treatment plan for you, by providing you with treatment options that are targeted specifically to your cancer.

How will the results benefit me?

Your personalised report will provide you with the genetic characteristics of your tumour, based on the variants or mutations that may be detected in these genes. We use this genetic information to help determine your likely response to certain types of treatment and highlight therapies and clinical trials you may be able to access, which are targeted specifically to treating the mutations identified in your tumour.

Included in the Oncomine™ Focus Tumour Analysis are genes which can be clinically targeted by current, on market oncology drugs and over 40 of the genes included have targeted drugs currently in clinical trial phases. The Oncomine™ Focus Tumour Analysis also enables detection of *NTRK* fusions in the *NTRK1*, *NTRK2*, and *NTRK3* genes, which can help patients determine their likely response if considering treatment with TRK inhibitors.

Genomic testing provides a personalised approach to your cancer treatment, giving you the best chance of survival. The aim of this testing is to provide you and your health care professional with the genetic characteristics of your tumour, which can then be matched with specific drugs that may help to increase the likelihood of disease-free progression.

Clinical trials of over 70,000 patients have shown that personalized therapy, based on genomic profiling of tumours, is the most effective way to improve treatment outcomes, with higher response rates, longer progression free and overall survival, and fewer deaths related to toxic effects across cancers. [1, 2, 3] Investing in genomic testing to obtain a complete diagnosis and to select appropriate, targeted therapy, is a small cost compared with the time and money that may be wasted on ill-chosen therapies. Genomic testing provides a powerful diagnostic tool, and every patient with cancer deserves an accurate diagnosis.

Questions? Let's Talk

CG Genomics Oncology aims to educate patients and their families on their cancer type and empower them with the knowledge to take control of their treatment plans. As each patient's case is unique, there is no "one size fits all" when it comes to testing. We encourage you to contact CG Genomics Oncology, and we can work with you and your oncologist/specialist, to determine what tests would benefit you.

Phone/WhatsApp: +852 6476 7844 | Email: info@connectgene.com | Web: www.cggenomicsoncology.com

CONNECTGENE Genomics Oncology

Unlock the Power of Genomics

What is tested in the Oncomine™ Focus Tumour Analysis?

The Oncomine™ Focus Tumour Analysis can detect relevant hotspots, single nucleotide variants (SNVs), copy number variations (CNVs), insertions/deletions (indels) and gene fusions from 52 oncogenes and tumour suppressor genes.

Hotspot Genes		Copy Number Variants	RNA Fusion Drivers	
AKT1	*IDH2*	*ALK*	*ABL1*	*PPARG*
ALK	*JAK1*	*AR*	*AKT3*	*RAF1*
AR	*JAK2*	*BRAF*	*ALK*	*RET*
BRAF	*JAK3*	*CCND1*	*AXL*	*ROS1*
CDK4	*KIT*	*CDK4*	*BRAF*	
CTNNB1	*KRAS*	*CDK6*	*EGFR*	
DDR2	*MAP2K1*	*EGFR*	*ERBB2*	
EGFR	*MAP2K2*	*ERBB2*	*ERG*	
ERBB2	*MET*	*FGFR1*	*ETV1*	
ERBB3	*MTOR*	*FGFR2*	*ETV4*	
ERBB4	*NRAS*	*FGFR3*	*ETV5*	
ESR1	*PDGFRA*	*FGFR4*	*FGFR1*	
FGFR2	*PIK3CA*	*KIT*	*FGFR2*	
FGFR3	*RAF1*	*KRAS*	*FGFR3*	
GNA11	*RET*	*MET*	*MET*	
GNAQ	*ROS1*	*MYC*	*NTRK1*	
HRAS	*SMO*	*MYCN*	*NTRK2*	
IDH1		*PDGFRA*	*NTRK3*	
		PIK3CA	*PDGFRA*	

The genes included in the Oncomine™ Focus Panel were selected using the Oncomine™ Knowledgebase, the world's largest curated collection of cancer genomic information. The Oncomine™ Knowledgebase collects published evidence from clinical trials, to assist in matching genetic mutations identified in tumours with relevant potential clinical therapeutic options, such as published therapeutic interventions and clinical trials.

Sample Requirements

To perform this test, we require a sample of tissue from your most recent biopsy. In most cases, previous biopsies can be used, and a new biopsy is usually not required.*

*Please contact us if your most recent biopsy was more than one year ago or no biopsy is a vailable.

How Do I Organise Testing?



References

1. Jardim, D. L., M. Schwaederle, C. Wei, J. J. Lee, D. S. Hong, A. M. Eggermont, R. L. Schilsky, J. Mendelsohn, V. Lazar and R. Kurzrock (2015). "Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval." J Natl Cancer Inst 107(11).
2. Schwaederle, M., M. Zhao, J. J. Lee, A. M. Eggermont, R. L. Schilsky, J. Mendelsohn, V. Lazar and R. Kurzrock (2015). "Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials." J Clin Oncol 33(32): 3817-3825
3. Subbiah, V. and R. Kurzrock (2016). "Universal genomic testing needed to win the war against cancer: Genomics is the diagnosis." JAMA Oncology 2(6): 719-720